Dyspepsia (Adult)

1. Topic Overview (Clinical Overview)

Summary

Dyspepsia is defined as epigastric pain or burning, postprandial fullness, or early satiation. [1] It affects 10-40% of the global population, making it one of the most common reasons for gastroenterology consultations. [2] The condition is broadly classified into uninvestigated dyspepsia (no endoscopy performed), organic dyspepsia (structural cause identified), and functional dyspepsia (no identifiable pathology despite investigation). [3]

The primary clinical challenge is risk stratification: identifying patients requiring urgent investigation to exclude malignancy versus those suitable for non-invasive management. Alarm features (dysphagia, weight loss, anaemia, GI bleeding) mandate urgent upper GI endoscopy (OGD). [4] In the absence of alarm features, first-line management involves either H. pylori test-and-treat or empirical proton pump inhibitor (PPI) therapy for 4-8 weeks. [5]

Helicobacter pylori is present in approximately 30-50% of patients with dyspepsia in Western populations and is strongly associated with peptic ulcer disease (PUD) and non-cardia gastric adenocarcinoma. [6] Eradication reduces ulcer recurrence by > 70% and modestly reduces gastric cancer risk. [7]

Functional dyspepsia (FD) accounts for 60-70% of cases after investigation and is diagnosed using Rome IV criteria. [8] It is subdivided into epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS), reflecting distinct symptom profiles and possible pathophysiological mechanisms. [9]

Key Facts

Clinical Pearls

"Alarm Features = Urgent OGD": Any alarm symptom mandates endoscopy within 2 weeks to exclude malignancy. [10]

"Age > 55 with New Dyspepsia = Lower Threshold for OGD": NICE recommends considering urgent endoscopy in patients ≥55 years with persistent unexplained dyspepsia. [11]

"Stop PPIs 2 Weeks Before H. pylori Testing": PPIs suppress H. pylori, reducing sensitivity of urea breath test (UBT) and stool antigen test. [12]

"Functional Dyspepsia ≠ Psychological Disorder": FD has measurable pathophysiological abnormalities including gastric hypersensitivity, impaired accommodation, and altered brain-gut signalling. [13]

"NSAIDs = Major Culprit": 20-30% of chronic NSAID users develop dyspepsia; 10-20% have ulcers on endoscopy. [14]

Why This Matters Clinically

Dyspepsia is extremely common and has significant impact on quality of life. Early detection of alarm features enables curative treatment of early gastric cancer (5-year survival > 90% for early gastric cancer vs less than 30% for advanced disease). [15] H. pylori eradication prevents ulcer complications (bleeding, perforation) and reduces gastric cancer risk. Functional dyspepsia, while benign, causes substantial morbidity and healthcare costs; effective management requires a biopsychosocial approach. [16]

---

2. Epidemiology

Incidence and Prevalence

Gender: Slight female preponderance (F:M ratio ~1.2-1.5:1), particularly for functional dyspepsia. [18]

Age: Prevalence increases with age. Organic causes (ulcers, cancer) more likely in patients > 50 years. [19]

Risk Factors

For Organic Dyspepsia (Peptic Ulcer Disease, Gastric Cancer)

For Functional Dyspepsia

---

3. Pathophysiology

Organic Dyspepsia

Peptic Ulcer Disease (PUD)

Mechanism: Imbalance between mucosal protective factors (mucus, bicarbonate, prostaglandins) and aggressive factors (acid, pepsin, H. pylori, NSAIDs).

• H. pylori: Causes chronic active gastritis, increases gastrin secretion (acid hypersecretion), and directly damages epithelium via urease, vacuolating cytotoxin (VacA), and CagA protein. [6]
• NSAIDs: Inhibit COX-1, reducing gastric prostaglandin E2 (PGE2), which normally stimulates mucus and bicarbonate secretion and maintains mucosal blood flow. [14]

Gastro-Oesophageal Reflux Disease (GORD)

Mechanism: Transient lower oesophageal sphincter relaxations (TLOSRs) allow gastric acid to reflux into oesophagus. Symptoms overlap with dyspepsia (epigastric burning, heartburn).

Gastric Malignancy

Mechanism: Chronic H. pylori infection induces atrophic gastritis → intestinal metaplasia → dysplasia → adenocarcinoma (Correa cascade). [15] Risk highest with CagA-positive strains.

---

Functional Dyspepsia (Rome IV)

Definition (Rome IV Criteria)

Must meet one or more of the following for ≥3 months (onset ≥6 months prior): [8]

1. Postprandial fullness (after normal-sized meal)
2. Early satiation (unable to finish normal meal)
3. Epigastric pain (not relieved by defecation, not gallbladder/sphincter of Oddi disorder)
4. Epigastric burning

AND: No evidence of structural disease on investigation (OGD, imaging).

Subtypes

Note: 30-40% have overlap syndrome (both PDS and EPS). [9]

Pathophysiological Mechanisms

Functional dyspepsia is multifactorial with heterogeneous mechanisms: [13]

---

Molecular and Cellular Mechanisms

H. pylori-Induced Gastric Inflammation

Bacterial Virulence Factors:

1. Urease: Hydrolyzes urea to ammonia and CO₂, neutralizing gastric acid and enabling bacterial survival. Ammonia damages epithelial cells directly. [45]

2. VacA (Vacuolating Cytotoxin A): Forms pores in epithelial cell membranes, causes vacuolation, induces apoptosis, and disrupts tight junctions. [45]

3. CagA (Cytotoxin-Associated Gene A): Translocated into host cells via Type IV secretion system, alters cell signaling pathways (activates NF-κB), induces inflammatory cytokine production (IL-8, IL-1β, TNF-α), and promotes cellular proliferation. CagA-positive strains have 3-4 times higher gastric cancer risk. [46]

4. Adhesins (BabA, SabA, OipA): Mediate bacterial adherence to gastric epithelium, facilitating colonization and preventing clearance.

Host Immune Response:

• Innate immunity: TLR4 and TLR5 recognition of H. pylori LPS and flagellin → NF-κB activation → IL-8 secretion → neutrophil recruitment.
• Adaptive immunity: Th1 and Th17 cell-mediated inflammation. IFN-γ and IL-17 amplify mucosal damage but fail to eradicate infection (bacterial immune evasion mechanisms). [47]
• Chronic inflammation: Persistent neutrophil and lymphocyte infiltration → chronic active gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → adenocarcinoma (Correa cascade). [15]

Acid Secretion Changes:

• Antral-predominant gastritis: Decreased somatostatin (D cells) → increased gastrin (G cells) → acid hypersecretion → duodenal ulcers.
• Corpus-predominant gastritis: Loss of parietal cells → hypochlorhydria → corpus atrophy → intestinal metaplasia → gastric cancer risk. [6]

---

NSAID-Induced Mucosal Injury

Topical (Direct) Effects:

• NSAIDs are weak acids (pKa 3-5); in acidic gastric environment (pH 1-2), they become lipophilic and penetrate epithelial cell membranes.
• Intracellular accumulation causes mitochondrial dysfunction, uncouples oxidative phosphorylation, depletes ATP, and triggers cell death. [14]

Systemic (COX-Mediated) Effects:

• COX-1 inhibition: Reduces prostaglandin E₂ (PGE₂) and prostacyclin (PGI₂) synthesis.
• PGE₂ roles in gastroprotection:
  • Stimulates mucus and bicarbonate secretion
  • Maintains mucosal blood flow
  • Inhibits gastric acid secretion
  • Promotes epithelial cell proliferation and repair
• Loss of PGE₂: Reduced mucus barrier → acid back-diffusion → epithelial injury → ulceration. [48]

COX-2 Selective Inhibitors (Coxibs):

• Spare COX-1, preserving gastric PGE₂ → 50-60% reduction in ulcer risk vs non-selective NSAIDs.
• However, COX-2 is upregulated during ulcer healing; coxibs may delay healing if ulcer already present. [14]

---

Functional Dyspepsia: Pathophysiological Mechanisms

1. Impaired Gastric Accommodation:

• Normal: Proximal stomach (fundus) relaxes reflexively during meal ingestion to accommodate food volume without pressure increase (receptive relaxation, mediated by vagal efferent nitric oxide [NO] release).
• In FD-PDS: Reduced fundic relaxation → early increase in intragastric pressure → mechanoreceptor activation → early satiety and fullness. Barostat studies show reduced accommodation in 40-50% of FD patients. [22]
• Mechanism: Impaired nitrergic neurotransmission, reduced fundic compliance, vagal dysfunction. [49]

2. Delayed Gastric Emptying (Gastroparesis):

• Present in 25-35% of FD patients (overlap with PDS).
• Mechanism: Impaired antral contractility, pyloric dysfunction, loss of interstitial cells of Cajal (gastric pacemaker cells). [23]
• Clinical correlation: Symptom severity does not correlate well with emptying rate; some patients with normal emptying have severe symptoms (suggests sensitivity is more important than motility). [50]

3. Visceral Hypersensitivity:

• Definition: Reduced sensory threshold for gastric/duodenal distension → pain at lower stimulus intensity.
• Mechanism: Peripheral sensitization (increased nociceptor excitability, inflammatory mediators, eosinophil/mast cell degranulation) + central sensitization (altered brain-gut axis processing, reduced descending pain inhibition). [13]
• Evidence: Barostat studies show lower pain thresholds in 30-40% of FD patients vs controls. [51]

4. Duodenal Eosinophilia and Low-Grade Inflammation:

• Findings: Increased duodenal eosinophils (≥20/HPF), mast cells, and intraepithelial lymphocytes in FD patients vs controls. [24]
• Mechanism: Low-grade immune activation → release of histamine, tryptase, nerve growth factor → nerve sensitization → visceral hypersensitivity.
• Triggers: Post-infectious (10-15% develop FD after acute gastroenteritis), food antigens (wheat, gluten sensitivity even without coeliac disease). [21,52]

5. Altered Brain-Gut Axis:

• Neuroimaging studies: FD patients show altered brain activation patterns in response to gastric distension (increased activation of insula, anterior cingulate cortex, reduced prefrontal cortex modulation). [53]
• Neurotransmitter dysregulation: Serotonin (5-HT), corticotropin-releasing factor (CRF), neuropeptide Y.
• Psychosocial factors: Anxiety and depression in 30-50% of FD patients; bidirectional relationship (psychological stress worsens symptoms, chronic symptoms cause psychological distress). [13]

6. Altered Gastric Microbiome:

• Emerging evidence suggests altered gastric bacterial composition (dysbiosis) in FD, independent of H. pylori.
• Mechanisms: Small intestinal bacterial overgrowth (SIBO), altered fermentation patterns, increased gut permeability. [54]

---

Rome IV Diagnostic Criteria (Detailed)

Functional Dyspepsia Definition (Rome IV, 2016)

Must include ONE OR MORE of the following for ≥3 months (onset ≥6 months before diagnosis): [8]

1. Postprandial fullness (bothersome, after ordinary-sized meals)
2. Early satiation (bothersome, unable to finish regular meal)
3. Epigastric pain (bothersome, not associated with bowel movements, not meeting criteria for gallbladder/sphincter of Oddi dysfunction)
4. Epigastric burning (bothersome)

AND:

• No evidence of structural disease (including at upper endoscopy) likely to explain symptoms

Exclusion Criteria:

• Symptoms predominantly relieved by defecation (suggests IBS, not FD)
• Symptoms meeting criteria for biliary pain (postprandial RUQ pain radiating to back)
• Symptoms meeting criteria for sphincter of Oddi dysfunction

Important: Rome IV requires symptoms to be "bothersome" (i.e., sufficient to impact quality of life or prompt medical consultation). Mild, infrequent symptoms do not meet criteria. [8]

---

Rome IV Subtypes

A. Postprandial Distress Syndrome (PDS):

Criteria (must include ONE OR BOTH):

1. Bothersome postprandial fullness ≥3 days/week
2. Bothersome early satiation ≥3 days/week

Supportive features:

• Upper abdominal bloating
• Postprandial nausea
• Excessive belching

Pathophysiology: Impaired accommodation (40-50%), delayed emptying (25-35%), duodenal eosinophilia.

Prevalence: ~60% of FD patients (most common subtype).

B. Epigastric Pain Syndrome (EPS):

Criteria (must include ONE OR BOTH):

1. Bothersome epigastric pain ≥1 day/week
2. Bothersome epigastric burning ≥1 day/week

Supportive features:

• Pain/burning localized to epigastrium
• May be induced or relieved by meal ingestion
• May be aggravated by emotional stress

Exclusion:

• Pain does NOT meet biliary pain criteria
• Pain does NOT improve with defecation or passage of flatus

Pathophysiology: Visceral hypersensitivity (30-40%), duodenal acid exposure, central sensitization.

Prevalence: ~40% of FD patients.

Overlap PDS-EPS: 30-40% of FD patients meet criteria for BOTH subtypes. [9]

---

Rome IV vs Rome III: Key Changes

Clinical Implication: Rome IV recognizes that many FD patients have overlapping meal-related (PDS) and pain-related (EPS) symptoms, reflecting heterogeneous pathophysiology. [8]

---

Differential Diagnosis (Expanded)

Key Differentials by Presentation Pattern

---

Organic Causes of Dyspepsia: Frequency After OGD

Key Point: 60-70% of patients undergoing OGD for dyspepsia have normal findings → functional dyspepsia diagnosis. This highlights the importance of careful patient selection for endoscopy. [3]

---

Advanced Investigation Strategies

When Standard OGD is Normal but Symptoms Persist

1. Gastric Emptying Scintigraphy (Gold Standard):

• Indication: Suspected gastroparesis (early satiety, postprandial fullness, vomiting, diabetes).
• Method: Radiolabelled solid meal (99mTc-labelled egg sandwich). Imaging at 0, 1, 2, 4 hours.
• Interpretation:
  • "Normal: \u003c10% retention at 4 hours"
  • "Delayed: \u003e10% retention at 4 hours (moderate: 10-15%, severe: \u003e35%)"
• Limitations: Poor symptom correlation; treatment based on symptoms, not emptying rate. [23]

2. Gastric Accommodation Testing (Barostat Study):

• Indication: Research setting. Suspected impaired accommodation (PDS).
• Method: Intragastric balloon inflated to measure volume-pressure relationship during fasting and post-meal.
• Interpretation: Reduced proximal gastric volume post-meal indicates impaired accommodation.
• Availability: Specialized centers only; not routine clinical practice. [22]

3. Wireless Motility Capsule (WMC):

• Indication: Suspected global GI dysmotility.
• Method: Ingestible capsule measures pH, pressure, temperature as it transits GI tract.
• Interpretation: Gastric emptying time, small bowel transit, colonic transit.
• Advantage: Non-invasive, ambulatory. Limitation: Expensive, limited availability. [55]

4. 24-Hour Oesophageal pH-Impedance Monitoring:

• Indication: GORD symptoms refractory to PPI (excludes acid/non-acid reflux).
• Method: Nasogastric catheter records pH and bolus movement (impedance).
• Interpretation:
  • Acid exposure time \u003e6% = pathological GORD
  • Symptom index (SI \u003e50%) or symptom association probability (SAP \u003e95%) = symptom-reflux correlation
• Value: Distinguishes GORD from functional heartburn. [56]

5. Duodenal Eosinophil Count:

• Indication: Refractory FD, suspected eosinophilic gastroenteritis.
• Method: Duodenal biopsies at OGD (≥6 samples from D2).
• Interpretation: ≥20 eosinophils/HPF suggests duodenal eosinophilia (present in 20-30% FD).
• Treatment: Trial of dietary modification (low-FODMAP, elimination diet), budesonide (off-label). [24]

6. Small Intestinal Bacterial Overgrowth (SIBO) Testing:

• Indication: Bloating, flatulence, diarrhoea-predominant symptoms.
• Method: Glucose or lactulose breath test (measures hydrogen/methane).
• Interpretation: Early rise in H₂ (\u003c90 min) suggests SIBO.
• Treatment: Rifaximin 550mg TDS for 14 days (non-absorbed antibiotic). [54]

---

Management: Evidence-Based Algorithm

Step 1: Initial Assessment (Primary Care)

A. History and Red Flag Screening:

• Age, duration, symptom pattern (meal-related vs pain-related)
• Medication review (NSAIDs, aspirin, bisphosphonates, iron)
• Alarm features (dysphagia, weight loss, GI bleeding, anaemia, mass, age \u003e55 with new symptoms)

B. Physical Examination:

• Epigastric tenderness (non-specific)
• Palpable mass, hepatomegaly, ascites (advanced cancer)
• Virchow's node, Sister Mary Joseph nodule (metastatic gastric cancer)

C. Initial Investigations (if no alarm features):

• FBC (exclude anaemia)
• Coeliac serology (tissue transglutaminase IgA + total IgA) if bloating/diarrhoea
• H. pylori testing (UBT or stool antigen)

D. Decision Point:

• Alarm features present → URGENT OGD (2-week wait)
• Age ≥55 + persistent new-onset dyspepsia → Consider urgent OGD
• Age \u003c55 + no alarms → Non-invasive management (proceed to Step 2)

---

Step 2: First-Line Management (No Alarm Features)

Option A: H. pylori Test-and-Treat Strategy

Who: All patients \u003c55 years, no alarm features, in regions with H. pylori prevalence \u003e10%. [1,7]

Advantages:

• Cures ulcers permanently (if H. pylori-related)
• Reduces gastric cancer risk (small benefit, NNT ~hundreds for cancer prevention)
• Avoids long-term PPI use
• Cost-effective in high-prevalence areas

Process:

1. Test: Urea breath test OR stool antigen (NOT serology)
2. Stop PPI 2 weeks before testing (antibiotics 4 weeks before)
3. If positive: Eradication therapy (see detailed regimens below)
4. Confirm eradication: UBT or stool antigen ≥4 weeks post-treatment (stop PPI 2 weeks before retest)

Option B: Empirical PPI Trial (4-8 Weeks)

Who:

• H. pylori-negative patients
• Patients in low H. pylori prevalence areas
• GORD-predominant symptoms (heartburn, regurgitation)
• When H. pylori testing unavailable

Regimen:

• Omeprazole 20mg OD (or equivalent PPI) for 4-8 weeks
• Take 30 minutes before breakfast (maximal acid suppression)

Expected Response:

• 30-40% symptom improvement in FD (NNT ~7-10 vs placebo) [34]
• 60-70% improvement if GORD-predominant
• If no response after 4 weeks, trial another 4 weeks OR switch to H2RA (ranitidine 150mg BD)

After 4-8 Weeks:

• Symptoms resolved: Step down to lowest effective dose OR on-demand therapy OR stop (attempt discontinuation)
• Symptoms persist: Proceed to Step 3

---

Step 3: Refractory Symptoms (First-Line Failure)

Definition: Symptoms persist despite:

• 4-8 week PPI trial
• H. pylori eradication (if positive)
• NSAID cessation

Actions:

A. Consider OGD (if not yet performed):

• Exclude organic pathology
• Duodenal biopsies for coeliac disease, eosinophilia
• If normal → diagnose functional dyspepsia

B. Review Diagnosis:

• Is this truly dyspepsia, or IBS (pain relieved by defecation)?
• Could this be biliary pain (RUQ, postprandial, radiates to back)?
• Could this be chronic pancreatitis (alcohol history, steatorrhoea)?

C. Functional Dyspepsia Management (Rome IV criteria met):

For PDS (Postprandial Fullness/Early Satiety):

Caution:

• Metoclopramide: Risk of tardive dyskinesia (1-2% with chronic use). Limit to 12 weeks. Avoid in elderly.
• Domperidone: QT prolongation risk. Avoid if cardiac disease, QTc \u003e470ms, or concurrent QT-prolonging drugs. FDA warning (not approved in US). [57]

For EPS (Epigastric Pain/Burning):

Key Point: Tricyclic antidepressants (TCAs) are the most evidence-based pharmacotherapy for functional dyspepsia. Mechanism: modulate visceral pain perception (central and peripheral), reduce gastric hypersensitivity. [38]

Counselling for TCAs:

• "This is used for nerve pain, not depression, at a much lower dose."
• Start 10mg nocte, increase by 10mg every 2 weeks to 25-50mg.
• Expect benefit after 4-6 weeks (neurostimulation effect takes time).
• Side effects: dry mouth, constipation, drowsiness (usually mild at low dose).

---

Step 4: Specialist Gastroenterology Referral

Indications:

• Refractory symptoms despite PPI + TCA + dietary measures
• Complex diagnostic uncertainty
• Failed second-line H. pylori eradication
• Consideration for specialist investigations (gastric emptying study, pH-impedance)

Specialist Options:

• Gastric electrical stimulation (GES): Investigational for severe gastroparesis (not routine). [69]
• Pyloric botulinum toxin injection: For refractory gastroparesis (limited evidence).
• Fundic relaxants (buspirone): 5-HT1A agonist, improves accommodation (10mg TDS). Weak evidence. [58]
• Neuromodulators (SSRIs, SNRIs): May help if significant anxiety/depression.
• Herbal therapies: STW 5 (Iberogast) and rikkunshito show modest benefit in some trials, though evidence remains limited. [67,68]

---

H. pylori Eradication: Detailed Regimens and Resistance Strategies

Regional Clarithromycin Resistance Rates

Principle: If local resistance \u003e15%, consider bismuth quadruple therapy first-line. [7,32]

---

First-Line Eradication Regimens

Regimen 1: Standard Triple Therapy (PPI + Amoxicillin + Clarithromycin)

Eradication Rate: 75-85% (declining due to clarithromycin resistance) [32]
Recommendation: 14 days superior to 7 days (Maastricht VI). NICE CG184 recommends 7 days, but international consensus favors 10-14 days. [7]

Regimen 2: Bismuth Quadruple Therapy (First-Line in High Resistance Areas)

Eradication Rate: 85-90% [33]
Advantage: Effective despite clarithromycin resistance
Disadvantage: Pill burden (high), GI side effects (nausea, black stools from bismuth)

Alternative: Pylera (single capsule containing bismuth subcitrate 140mg + metronidazole 125mg + tetracycline 125mg). Dose: 3 capsules QDS for 10 days + PPI BD. [59]

---

Second-Line Eradication (If First-Line Fails)

Regimen 3: Levofloxacin-Based Triple Therapy

Eradication Rate: 75-85% [7]
Concern: Fluoroquinolone resistance increasing (5-20% in some regions). Reserve for second-line.

Regimen 4: High-Dose Dual Therapy (PPI + Amoxicillin)

Eradication Rate: 70-80% [60]
Rationale: High-dose PPI (QDS) maintains gastric pH \u003e6, enabling amoxicillin efficacy (pH-dependent). Resistance to amoxicillin is rare. [60]

---

Third-Line Eradication (If Second-Line Fails)

Approach: Culture and Sensitivity Testing via endoscopic biopsy

• Obtain antral biopsies for H. pylori culture
• Test antibiotic sensitivities (clarithromycin, metronidazole, levofloxacin, tetracycline)
• Tailor therapy based on susceptibility

Empirical Third-Line (if culture not feasible):

• Rifabutin-based triple therapy: PPI + Rifabutin 150mg BD + Amoxicillin 1g BD for 10-14 days
• Eradication: ~70-80%
• Caution: Rifabutin is anti-TB drug; risk of resistance. Reserve for failure of 2+ regimens. [7]

---

Factors Affecting Eradication Success

---

PPI Therapy: Advanced Prescribing

PPI Pharmacokinetics and CYP2C19 Polymorphisms

CYP2C19 Enzyme: Metabolizes PPIs (except rabeprazole, partially).

Genotypes:

• Rapid Metabolizers (RM): ~30% of Caucasians. Rapid PPI clearance → reduced acid suppression → lower H. pylori eradication rates.
• Normal Metabolizers (NM): ~50-60%.
• Poor Metabolizers (PM): ~10-20% (especially Asians). Slow PPI clearance → high acid suppression → better eradication success. [62]

Clinical Implications:

• If first-line eradication fails, consider high-dose PPI (e.g., omeprazole 40mg BD) or esomeprazole (less CYP2C19-dependent).
• Rabeprazole: Metabolized non-enzymatically; less affected by CYP2C19 polymorphism. [62]

---

PPI Dosing for Different Indications

---

Long-Term PPI Use: Risk-Benefit Balance

Benefits:

• Effective acid suppression
• Ulcer healing and prevention
• Symptom control in GORD/FD

Potential Risks (observational data, causality uncertain): [35]

Management of Long-Term PPI:

1. Annual review of indication
2. Step-down trial: Attempt lowest effective dose or on-demand therapy
3. Do NOT stop abruptly if \u003e8 weeks continuous use (risk of rebound acid hypersecretion over 2-4 weeks)
4. Taper: Reduce to alternate days or H2RA (ranitidine 150mg BD) before stopping
5. Monitor: FBC (anaemia), U&E (CKD), Mg²⁺ (if on diuretics), B12 (if \u003e2 years use)

Key Point: Benefits of PPI in established indications (ulcers, GORD) outweigh potential risks. However, inappropriate long-term use without indication should be stopped. [35]

---

NSAID-Associated Dyspepsia and Ulcer Prevention

Risk Stratification for NSAID Users

High-Risk Patients (require gastroprotection):

1. Age \u003e65 years
2. History of peptic ulcer or GI bleeding
3. Concurrent anticoagulant (warfarin, DOAC) or antiplatelet (aspirin, clopidogrel)
4. Concurrent corticosteroid
5. High-dose or multiple NSAIDs
6. Serious comorbidity (CVD, CKD, hepatic disease)

Moderate-Risk Patients:

• Age 60-65
• H. pylori-positive
• Dyspepsia history

Low-Risk Patients:

• Age \u003c60, no risk factors

---

Prevention Strategies

Strategy 1: COX-2 Selective Inhibitor (Coxib) Alone

• Drug: Celecoxib 200mg OD/BD, etoricoxib 60-90mg OD
• Ulcer Risk Reduction: 50-60% vs non-selective NSAID [41]
• Cardiovascular Risk: Coxibs increase CV events (MI, stroke) if pre-existing CVD. Contraindicated if recent MI, severe heart failure, or stroke.
• Recommendation: Use in moderate-risk patients without CVD.

Strategy 2: Non-Selective NSAID + PPI

• Drugs: Ibuprofen/naproxen/diclofenac + Omeprazole 20mg OD
• Ulcer Risk Reduction: 60-70% vs NSAID alone [41]
• Recommendation: Use in moderate-risk patients.

Strategy 3: COX-2 Inhibitor + PPI (Dual Protection)

• Drugs: Celecoxib + Omeprazole
• Ulcer Risk Reduction: \u003e80% vs non-selective NSAID alone [41]
• Recommendation: Use in high-risk patients (e.g., previous ulcer bleed + NSAID essential).

Evidence: CONDOR Trial (2010): Celecoxib alone vs Diclofenac + Omeprazole. Both strategies had similar low ulcer rates (~0.3%). Celecoxib + PPI not studied but likely superior. [41]

---

H. pylori Eradication in NSAID Users

Question: Should H. pylori be eradicated before starting long-term NSAID?

Answer: YES, if feasible. [63]

Evidence:

• H. pylori + NSAID: Synergistic ulcer risk (OR 6-7 for ulcer if both present vs neither). [63]
• Eradication before NSAID: Reduces ulcer risk by ~50%. [64]

Recommendation (NICE, Maastricht VI):

• Test for H. pylori before starting long-term NSAID (if not already on).
• Eradicate if positive.
• Note: Eradication alone (without PPI) is insufficient protection if NSAID continued. Combine eradication + PPI. [7,64]

---

Aspirin and Gastric Protection

Low-Dose Aspirin (75-150mg): Used for CV protection.

GI Risk: 2-4 times increased ulcer/bleeding risk vs placebo. [65]

Who Needs PPI:

• Previous peptic ulcer or GI bleeding → PPI co-prescription mandatory
• Age \u003e65 + additional risk factor → Consider PPI
• Concurrent anticoagulant or second antiplatelet → PPI recommended

Evidence: PPI reduces aspirin-related ulcer bleeding by ~60-70%. [65]

H. pylori Eradication: Reduces ulcer risk in aspirin users (eradicate if positive). [7]

---

Clinical Decision-Making: Case-Based Approach

Case 1: 38-Year-Old Woman, Epigastric Burning, No Alarm Features

Presentation: 3 months epigastric burning, worse after meals, no weight loss, no dysphagia. Occasional ibuprofen for headaches.

Management:

1. Stop ibuprofen → switch to paracetamol
2. H. pylori testing (UBT or stool antigen)
3. If H. pylori positive: Eradication therapy (triple therapy 14 days)
4. If H. pylori negative: PPI trial (omeprazole 20mg OD for 4-8 weeks)
5. Follow-up: Review at 8 weeks. If improved, stop PPI. If not, consider OGD.

Rationale: Age \u003c55, no alarms → non-invasive management appropriate. NSAID cessation may resolve symptoms alone.

---

Case 2: 68-Year-Old Man, Dyspepsia + 6kg Weight Loss

Presentation: 8 weeks dyspepsia, unintentional 6kg weight loss, reduced appetite.

Management:

1. URGENT OGD (2-week wait referral)
2. Bloods: FBC (anaemia), coeliac serology
3. Do NOT start PPI before OGD (may mask cancer)

OGD Findings:

• If gastric cancer: MDT discussion, CT staging, oncology referral
• If benign ulcer: Multiple biopsies (exclude malignancy), H. pylori testing, PPI therapy

Rationale: Age \u003e55 + weight loss = alarm feature. Gastric cancer must be excluded urgently. Incidence of cancer ~5-10% in this scenario. [26]

---

Case 3: 45-Year-Old with Functional Dyspepsia (Normal OGD), PPI Non-Responder

Presentation: Postprandial fullness, early satiety for 12 months. OGD normal. H. pylori-negative. 8 weeks PPI (omeprazole 20mg OD) → no benefit.

Diagnosis: Functional Dyspepsia - Postprandial Distress Syndrome (PDS) per Rome IV.

Management:

1. Dietary modification: Low-fat, small frequent meals, avoid triggers (caffeine, alcohol, fatty foods)
2. Prokinetic trial: Metoclopramide 10mg TDS (before meals) for 8 weeks
   • Counsel: Risk of drowsiness, avoid driving initially
   • Limit to 12 weeks (tardive dyskinesia risk)
3. If no response: Consider amitriptyline 10-25mg nocte (neuromodulator)
4. Refer gastroenterology if refractory: Consider gastric emptying study, psychological therapy (CBT)

Rationale: FD-PDS likely impaired accommodation/delayed emptying → prokinetic reasonable. Amitriptyline effective for both PDS and EPS. [36,38]

---

Case 4: 72-Year-Old with Rheumatoid Arthritis, Requires Long-Term NSAID

Presentation: RA, requires diclofenac for joint pain. Develops dyspepsia on diclofenac 50mg BD.

Risk Factors: Age \u003e65, long-term NSAID → HIGH RISK for ulcer.

Management Options:

1. Stop NSAID if possible → trial paracetamol, topical NSAID, or intra-articular steroid
2. If NSAID essential:
   • Switch to celecoxib 200mg OD + omeprazole 20mg OD (dual protection)
   • OR: Continue diclofenac + omeprazole 20mg OD (if no CVD)
3. Test and eradicate H. pylori (if positive, eradication reduces ulcer risk)
4. If dyspepsia persists despite PPI: OGD to exclude ulcer

Rationale: High-risk patient requires gastroprotection. Celecoxib + PPI combination provides \u003e80% ulcer risk reduction. [41]

---

Prognosis: Long-Term Outcomes

Functional Dyspepsia

Natural History: [44]

• Chronic relapsing condition: Most patients have fluctuating symptoms over years.
• 30-50% improve over 5-10 years (spontaneous remission or adaptation).
• 20-30% deteriorate (increased symptom severity, development of IBS overlap).
• No increased mortality: Benign condition, no cancer risk.

Quality of Life Impact: [16]

• Significant impairment: Comparable to IBS, inflammatory bowel disease, GORD.
• Work productivity loss, healthcare costs (~$18 billion annually in US).
• Psychological comorbidity (anxiety, depression) in 30-50%, bidirectional relationship.

Predictors of Poor Outcome:

• Severe baseline symptoms
• Psychological comorbidity (anxiety, depression, somatization)
• Poor treatment response
• Delayed gastric emptying
• Duodenal eosinophilia

---

Peptic Ulcer Disease

With H. pylori Eradication: [6]

• Ulcer healing: 80-90% within 8 weeks
• Ulcer recurrence: Reduced from 60%/year (no eradication) to \u003c5%/year (successful eradication)
• Bleeding/perforation risk: Reduced by \u003e90%

NSAID Ulcers (with NSAID cessation + PPI): [14]

• Healing: 80-90% within 8 weeks
• Recurrence: \u003c10%/year if NSAID stopped
• If NSAID continued: 30-40% recurrence despite PPI

---

Gastric Cancer

Key Message: Early detection saves lives. Urgent OGD for alarm features enables curative treatment. Japan/Korea have population gastric cancer screening (high incidence) → 50-60% detected at early stage → 5-year survival greater than 60% (serum pepsinogen + H. pylori antibody—"ABC method"). [15,70] UK: most detected at advanced stage → survival \u003c30%. [15]

---

Key Guidelines Summary

---

Viva Voce Preparation

Opening Statement (Dyspepsia)

"Dyspepsia is defined as epigastric pain or burning, postprandial fullness, or early satiation. It affects 10-40% of the population and is classified into uninvestigated dyspepsia, organic dyspepsia (structural cause identified), and functional dyspepsia (Rome IV diagnosis of exclusion). The primary clinical challenge is risk stratification to identify patients requiring urgent endoscopy to exclude malignancy versus those suitable for non-invasive management."

---

Key Facts to Mention

Epidemiology:

• Prevalence: 10-40% globally; ~4% consult primary care annually. [2]
• Functional dyspepsia: 60-70% of investigated cases. [3]

Alarm Features (ALARM mnemonic):

• Anaemia, Loss of weight, Anorexia, Recent onset/rapidly progressive, Melaena/haematemesis, Dysphagia
• Age ≥55 with new-onset dyspepsia
• Positive predictive value for cancer: 5-10% in primary care. [26]

H. pylori:

• Prevalence: 30-50% in Western populations. [6]
• Eradication: Reduces ulcer recurrence from 60%/year to \u003c5%/year. [6]
• Standard triple therapy: PPI + amoxicillin + clarithromycin for 14 days (Maastricht VI). [7]
• Eradication success: 75-85% (declining due to resistance). [32]

Functional Dyspepsia (Rome IV):

• Subtypes: Postprandial Distress Syndrome (meal-related) and Epigastric Pain Syndrome (pain/burning). [8]
• Pathophysiology: Impaired accommodation (40-50%), delayed emptying (25-35%), visceral hypersensitivity (30-40%), duodenal eosinophilia (20-30%). [22-24]
• Management: PPIs (NNT ~7-10), tricyclic antidepressants (NNT 5-7), prokinetics, psychological therapy. [34,38]

Management Algorithm:

• Alarm features → Urgent OGD (2WW). [10,11]
• No alarms, age \u003c55 → H. pylori test-and-treat OR PPI trial. [5]
• Refractory → OGD + functional dyspepsia management (TCAs, CBT). [1]

---

Common Examiner Questions and Model Answers

Q1: What are the Rome IV criteria for functional dyspepsia?

A: "The Rome IV criteria require one or more of the following symptoms for at least 3 months, with onset at least 6 months prior: (1) bothersome postprandial fullness, (2) bothersome early satiation, (3) bothersome epigastric pain, or (4) bothersome epigastric burning. Importantly, there must be no evidence of structural disease on investigation, including upper endoscopy. The condition is subdivided into Postprandial Distress Syndrome (PDS) for meal-related symptoms and Epigastric Pain Syndrome (EPS) for pain/burning symptoms, with overlap allowed."

Q2: How do you investigate a 42-year-old with dyspepsia and no alarm features?

A: "For a patient under 55 with no alarm features, I would pursue non-invasive management per NICE guidelines. First, I would review medications, particularly NSAIDs, and perform baseline bloods including FBC and coeliac serology if there's bloating or diarrhoea. I would then test for H. pylori using urea breath test or stool antigen—ensuring any PPI is stopped 2 weeks before testing. If positive, I'd provide eradication therapy with triple therapy for 14 days. If negative, I'd offer an empirical PPI trial for 4-8 weeks. I would only consider endoscopy if symptoms are refractory or alarm features develop."

Q3: What is your first-line eradication therapy for H. pylori?

A: "The current Maastricht VI consensus recommends PPI-based triple therapy: a proton pump inhibitor (omeprazole 20-40mg twice daily), amoxicillin 1g twice daily, and clarithromycin 500mg twice daily for 14 days. Duration of 14 days is preferred over 7 days as it improves eradication rates by 5-10%. Alternatively, in regions with high clarithromycin resistance (over 15%), bismuth-based quadruple therapy is recommended first-line, consisting of a PPI, bismuth, metronidazole, and tetracycline for 10-14 days. After completing eradication therapy, I would perform a test-of-cure using urea breath test at least 4 weeks post-treatment, ensuring the PPI has been stopped for 2 weeks beforehand."

Q4: A patient has failed PPI and H. pylori eradication. OGD is normal. What next?

A: "This patient meets Rome IV criteria for functional dyspepsia. I would first determine the predominant subtype: if meal-related fullness and early satiety predominate, this suggests Postprandial Distress Syndrome, and I'd recommend dietary modification with small, low-fat meals, and consider a trial of a prokinetic agent such as metoclopramide 10mg three times daily before meals, limiting duration to 12 weeks due to tardive dyskinesia risk. If epigastric pain or burning predominates, suggesting Epigastric Pain Syndrome, I would recommend a tricyclic antidepressant such as amitriptyline starting at 10-25mg at night, which has an NNT of 5-7 and modulates visceral pain perception. I would explain this is used for nerve pain, not depression. If symptoms remain refractory, I'd refer to gastroenterology for consideration of psychological therapy such as CBT or hypnotherapy, which has strong evidence with an NNT of 4-6."

Q5: What are the risks of long-term PPI use?

A: "Long-term PPI use has been associated with several risks in observational studies, though causality is uncertain. These include a 30-40% increased risk of hip fracture (potentially due to reduced calcium absorption), a 50-100% increased risk of C. difficile infection (reduced gastric acid barrier), hypomagnesaemia (particularly in patients on diuretics), vitamin B12 deficiency with use beyond 2-3 years (requiring acid for B12 cleavage), and associations with chronic kidney disease, though this is controversial. Fundic gland polyps are common with long-term use but are benign with no malignant potential. The key is to ensure there's an ongoing indication, use the lowest effective dose, attempt step-down or on-demand therapy where possible, and conduct annual medication reviews. Benefits in established indications such as peptic ulcers and GORD generally outweigh these potential risks."

---

Common Mistakes to Avoid (Exam Failures)

❌ Missing alarm features: Always ask about dysphagia, weight loss, GI bleeding, anaemia. These mandate urgent OGD.

❌ Using H. pylori serology for diagnosis: Serology remains positive after eradication. Use UBT or stool antigen.

❌ Testing for H. pylori while on PPI: PPIs suppress H. pylori → false negatives. Stop PPI 2 weeks before testing.

❌ Not confirming H. pylori eradication: Test-of-cure is mandatory for peptic ulcer disease patients (bleeding risk if eradication fails).

❌ Prescribing long-term PPI without indication: Always review PPI indication annually and attempt step-down.

❌ Ignoring NSAIDs as a cause: 20-30% of chronic NSAID users have ulcers. Always review medication history.

❌ Failing to recognize functional dyspepsia: 60-70% have normal OGD. Rome IV diagnosis requires proactive management (not "it's all normal, nothing we can do").

❌ Using metoclopramide long-term: Limit to 12 weeks due to tardive dyskinesia risk (1-2% with chronic use).

❌ Not offering TCAs for refractory functional dyspepsia: Amitriptyline is the most evidence-based therapy (NNT 5-7).

---

4. Clinical Presentation

Symptoms of Dyspepsia

Core Symptoms

Symptom Patterns (Clues to Diagnosis)

---

ALARM Features (Red Flags)

Alarm features indicate higher risk of serious pathology (cancer, complicated PUD) and mandate urgent investigation (OGD within 2 weeks). [4,10]

ALARM Mnemonic (Extended)

Additional Red Flags

• Palpable epigastric mass (advanced gastric cancer)
• Persistent vomiting (gastric outlet obstruction)
• Previous gastric surgery (increased cancer risk)
• Family history of upper GI cancer (especially 1st degree relative less than 50 years)
• Age > 55 with new-onset dyspepsia (NICE threshold for 2-week wait referral) [11]

Important: Alarm features have moderate sensitivity (50-70%) but low specificity for cancer. PPV is 5-10% in primary care. However, they remain the best available risk stratification tool. [26]

---

5. Clinical Examination

General Inspection

Abdominal Examination

Systemic Signs

Note: Physical examination is usually normal in uncomplicated dyspepsia and functional dyspepsia. [3]

---

6. Investigations

When to Investigate: Clinical Pathway

Urgent OGD (2-Week Wait) [10,11]

Indications:

• Any alarm feature (dysphagia, weight loss, GI bleeding, anaemia, palpable mass)
• Age ≥55 years with new-onset persistent dyspepsia
• Previous gastric surgery + new symptoms
• Family history of gastric cancer + persistent symptoms

Routine OGD (Non-Urgent)

Indications:

• Persistent dyspepsia refractory to 4-8 weeks PPI trial
• H. pylori eradication failure + ongoing symptoms
• Recurrent dyspepsia requiring repeated PPI courses
• Patient preference (after discussion of risks/benefits)

No OGD Required (Non-Invasive Management)

Criteria:

• Age less than 55 years
• No alarm features
• Symptoms less than 4-8 weeks duration
• Suitable for H. pylori test-and-treat or PPI trial

---

Helicobacter pylori Testing

Test Selection

Key Point: Stop PPIs for 2 weeks and antibiotics for 4 weeks before non-invasive testing (UBT, stool antigen) to avoid false negatives. [12]

---

Blood Tests

---

Upper GI Endoscopy (OGD)

Findings on OGD

Biopsy Protocol at OGD:

• Gastric ulcers: Multiple biopsies (6-8) from ulcer edge to exclude malignancy.
• H. pylori detection: CLO test (rapid urease test) + histology from antrum and body.
• Suspected coeliac disease: Duodenal bulb + D2 biopsies (≥4 samples).

---

Imaging (If OGD Normal or Contraindicated)

---

7. Management

Management Algorithm (Stepwise Approach)

DYSPEPSIA PRESENTATION
        ↓
┌───────────────────────────┐
│ ALARM FEATURES PRESENT?   │
└───────────────────────────┘
        ↓ YES                    NO ↓
┌────────────────────┐     ┌──────────────────────┐
│ URGENT OGD (2WW)   │     │ Age > 55? New onset?  │
│ Refer within       │     └──────────────────────┘
│ 2 weeks            │            ↓ YES        NO ↓
└────────────────────┘     ┌──────────────┐  ┌────────────────┐
                           │ Consider OGD │  │ Non-Invasive   │
                           │ (NICE NG12)  │  │ Management     │
                           └──────────────┘  └────────────────┘
                                                      ↓
                                            ┌─────────────────────┐
                                            │ H. pylori Test      │
                                            │ (UBT or Stool Ag)   │
                                            └─────────────────────┘
                                              ↓             ↓
                                         POSITIVE       NEGATIVE
                                              ↓             ↓
                                    ┌──────────────┐  ┌──────────┐
                                    │ Eradication  │  │ PPI Trial│
                                    │ Therapy      │  │ 4-8 weeks│
                                    │ (7-14 days)  │  └──────────┘
                                    └──────────────┘       ↓
                                         ↓           ┌──────────────┐
                                    ┌──────────┐    │ Symptoms     │
                                    │ Confirm  │    │ Resolved?    │
                                    │ Eradica- │    └──────────────┘
                                    │ tion UBT │      ↓         ↓
                                    │ (≥4 wks) │    YES        NO
                                    └──────────┘      ↓         ↓
                                         ↓        ┌────┐  ┌─────────┐
                                    ┌──────────┐  │Stop│  │ OGD or  │
                                    │ Success? │  │PPI │  │ Reassess│
                                    └──────────┘  └────┘  └─────────┘
                                      ↓       ↓
                                    YES      NO
                                     ↓        ↓
                                 ┌────┐  ┌────────────┐
                                 │Stop│  │ 2nd Line   │
                                 │    │  │ Eradication│
                                 └────┘  └────────────┘

---

1. Lifestyle Modifications

Note: Lifestyle advice has limited evidence in functional dyspepsia but is low-risk and may benefit subsets. [31]

---

2. Medication Review

Stop or Reduce:

• NSAIDs / Aspirin: If possible, discontinue. If essential (e.g., cardiovascular protection), co-prescribe PPI. [14]
• Bisphosphonates: Consider alternative formulation (IV zoledronate) if dyspepsia severe.
• Iron Supplements: Switch to alternate-day dosing or IV iron if oral poorly tolerated.
• Calcium Channel Blockers / Nitrates: May worsen GORD (lower oesophageal sphincter relaxation).

---

3. H. pylori Test-and-Treat Strategy

First-Line Eradication Therapy [7,32]

Standard Triple Therapy (7-14 days):

Alternative (Penicillin Allergy):

Duration: 14 days superior to 7 days (eradication rates 85-90% vs 75-80%). [32] NICE CG184 recommends 7 days, but Maastricht VI recommends 10-14 days due to increasing clarithromycin resistance. [7,32]

Eradication Rates:

• Triple therapy: 75-85% (declining due to clarithromycin resistance in many regions). [7]
• Bismuth quadruple therapy: 85-90%. [33]

---

Second-Line Eradication (If First-Line Fails) [7,33]

Bismuth Quadruple Therapy (10-14 days):

Alternative Second-Line (If Bismuth Unavailable):

• Levofloxacin-based triple therapy: PPI + Levofloxacin 500mg OD + Amoxicillin 1g BD for 10-14 days. [7]
• Vonoprazan-based dual therapy: Emerging in Japan—vonoprazan (potassium-competitive acid blocker) + amoxicillin achieves 85-90% eradication with shorter duration, though not yet widely available outside Asia. [66]
• Culture and sensitivity: If second-line fails, consider endoscopy with culture to guide antibiotic selection.

---

Confirmation of Eradication

Test ≥4 weeks after completion of therapy:

• Urea Breath Test (UBT) (preferred)
• Stool Antigen Test

Critical: Stop PPI for 2 weeks before testing to avoid false negatives. [12]

Who to retest:

• All patients with peptic ulcer disease (bleeding risk if eradication fails).
• Patients with persistent symptoms post-treatment.
• Optional for uncomplicated dyspepsia (but recommended per Maastricht VI). [7]

---

4. Proton Pump Inhibitor (PPI) Therapy

Indications for PPI Trial (4-8 Weeks)

1. H. pylori-negative uninvestigated dyspepsia (no alarm features, age less than 55). [5]
2. Post-eradication symptoms (after confirmed H. pylori eradication).
3. GORD-predominant symptoms (heartburn, regurgitation).
4. Empirical therapy when H. pylori testing not immediately available.

Dosing

Duration: 4-8 weeks. [5] If symptoms resolve, attempt step-down or discontinuation. If symptoms recur, restart PPI at lowest effective dose.

Evidence: PPI therapy achieves symptom relief in 30-40% of functional dyspepsia (NNT ~7-10 vs placebo). [34] Effect is modest and similar to placebo in many trials, but remains first-line due to safety and availability.

---

Long-Term PPI Use: Risks and Monitoring

Potential Risks (mostly observational data; causality unclear): [35]

• Bone Fracture (hip, wrist, spine): OR 1.3-1.4 with long-term use (> 1 year).
• C. difficile Infection: OR 1.5-2.0.
• Hypomagnesaemia: Rare; monitor if on diuretics or long-term PPI.
• Vitamin B12 Deficiency: Risk with > 2-3 years continuous use.
• Chronic Kidney Disease: Observational association; causality uncertain.
• Fundic Gland Polyps: Benign; no malignant potential.

Management:

• Use lowest effective dose.
• Attempt intermittent or on-demand therapy if possible.
• Annual review of indication in primary care.
• Do not stop abruptly if on long-term therapy (risk of rebound acid hypersecretion).

---

5. Functional Dyspepsia Management

Diagnosis: Rome IV criteria + negative OGD (no ulcer, cancer, significant inflammation).

Management Approach (Tailored to Subtype)

Postprandial Distress Syndrome (PDS)

Epigastric Pain Syndrome (EPS)

Both Subtypes

Key Point: Tricyclic antidepressants (TCAs) are the most evidence-based pharmacotherapy for functional dyspepsia, particularly EPS. Start low (10mg), titrate slowly. [38]

---

6. NSAID-Associated Dyspepsia

Management Strategy

1. Discontinue NSAID if possible.
2. If NSAID essential:
   • Switch to COX-2 selective inhibitor (celecoxib) + PPI. [41]
   • Use lowest effective dose for shortest duration.
3. PPI co-prescription if NSAID cannot be stopped:
   • Standard dose PPI (omeprazole 20mg OD or equivalent).
   • Reduces ulcer risk by 60-70%. [41]

High-Risk Patients (require PPI + COX-2 inhibitor or stop NSAID):

• Age > 65
• Previous peptic ulcer or GI bleeding
• Concurrent aspirin, anticoagulant, or corticosteroid
• Multiple NSAIDs

---

7. Refractory Dyspepsia

Definition: Persistent symptoms despite:

• H. pylori eradication (confirmed)
• 8-week PPI trial
• Medication review (NSAIDs stopped)

Next Steps

1. OGD if not yet performed.
2. Review diagnosis: Consider alternative diagnoses (coeliac disease, chronic pancreatitis, biliary dyskinesia, IBS overlap).
3. Functional dyspepsia therapies: TCAs, psychological therapies.
4. Gastroenterology referral for further investigation (gastric emptying study, impedance-pH monitoring if GORD suspected).

---

8. Complications

Complications of Peptic Ulcer Disease

Complications of Gastric Cancer

---

9. Prognosis & Outcomes

Functional Dyspepsia

• Natural history: Chronic relapsing condition. 30-50% report improvement over 5-10 years, but many have persistent symptoms. [44]
• Quality of life: Significantly impaired (comparable to IBS, GORD). [16]
• Mortality: No increased mortality. Benign condition.

Peptic Ulcer Disease

• H. pylori eradication: Ulcer healing in 80-90%. Recurrence reduced from ~60%/year to less than 5%/year. [6]
• NSAID ulcers: Healing with PPI in 80-90% within 8 weeks if NSAID stopped. [14]

Gastric Cancer

Key Point: Early detection via OGD for alarm features improves outcomes dramatically. [15]

---

10. Evidence & Guidelines

Key Clinical Guidelines

---

11. Exam Scenarios & MCQs

Scenario 1: Uninvestigated Dyspepsia (Age less than 55)

Stem: A 42-year-old woman presents with 3 months of epigastric discomfort and bloating. No alarm features. She takes occasional ibuprofen for headaches. What is the most appropriate initial management?

Answer: H. pylori testing (UBT or stool antigen) → If positive, eradication therapy. If negative, PPI trial 4-8 weeks. Also advise stop ibuprofen and switch to paracetamol.

---

Scenario 2: Dyspepsia with Alarm Features

Stem: A 62-year-old man with 6 weeks of dyspepsia and unintentional 5kg weight loss. What is the next step?

Answer: Urgent upper GI endoscopy (OGD) via 2-week wait pathway. Age > 55 + weight loss = alarm features mandating investigation to exclude gastric cancer. [11]

---

Scenario 3: H. pylori Eradication

Stem: A patient completes triple therapy for H. pylori. When should you perform a test-of-cure urea breath test?

Answer: At least 4 weeks after completion of eradication therapy, having stopped PPI for 2 weeks before the test. [7,12]

---

Scenario 4: PPI Non-Response

Stem: A 38-year-old with functional dyspepsia (normal OGD, H. pylori-negative) has ongoing epigastric pain despite 8 weeks of omeprazole 20mg OD. What is the next best management?

Answer: Tricyclic antidepressant (e.g., amitriptyline 10-25mg nocte). TCAs are effective for functional dyspepsia, particularly EPS, with NNT ~5-7. [38]

---

Scenario 5: NSAID User

Stem: A 70-year-old with rheumatoid arthritis develops dyspepsia on long-term diclofenac. He requires ongoing NSAID therapy. What is the best strategy to reduce ulcer risk?

Answer: Switch to COX-2 selective inhibitor (celecoxib) + PPI co-prescription. This combination reduces ulcer risk by > 80% vs non-selective NSAID alone. [41]

---

MCQ: Alarm Feature PPV

Question: What is the approximate positive predictive value (PPV) of alarm features for gastric cancer in primary care patients with dyspepsia?

A) less than 1%
B) 5-10%
C) 20-30%
D) 40-50%
E) > 60%

Answer: B) 5-10%. Alarm features have moderate sensitivity but low specificity; PPV is ~5-10% in primary care settings. [26] However, they remain the best available risk stratification tool.

---

12. Triage & Referral Pathways

---

13. Patient/Layperson Explanation

What is Dyspepsia?

Dyspepsia (also called "indigestion") is pain or discomfort in your upper tummy. You might feel:

• A burning or aching in your stomach
• Fullness or bloating after eating
• Feeling full very quickly when eating
• Heartburn (burning in your chest)

What causes it?

• Stomach bug (Helicobacter pylori): A common germ that can cause stomach ulcers.
• Painkillers (NSAIDs): Medicines like ibuprofen can irritate your stomach.
• Acid reflux (GORD): Stomach acid coming up into your food pipe.
• Stress and diet: Fatty foods, caffeine, alcohol, and stress can worsen symptoms.
• Functional dyspepsia: Your stomach is sensitive, but tests are normal (most common cause).

How is it treated?

1. Test for H. pylori: A simple breath or stool test. If positive, take a course of antibiotics + acid-reducing medicine.
2. Acid-reducing medicine (PPI): Like omeprazole. Taken for 4-8 weeks.
3. Lifestyle changes: Stop smoking, reduce alcohol, avoid trigger foods, lose weight if overweight.

When should I see a doctor urgently?

See a doctor immediately if you have:

• Difficulty swallowing
• Unintentional weight loss (> 3kg)
• Vomiting blood (red or coffee-ground colour)
• Black tarry stools (melaena)
• Severe tummy pain

These symptoms can be signs of serious problems like ulcers or cancer and need urgent investigation.

Will it go away?

• If caused by H. pylori or painkillers, it usually improves with treatment.
• If functional dyspepsia, symptoms may come and go, but it's not dangerous. Your doctor can help manage symptoms.

Key Counselling Points

1. "Complete the full antibiotic course": If you have H. pylori, finishing all the antibiotics is essential to clear the infection.
2. "Stop taking ibuprofen if possible": Switch to paracetamol for pain relief.
3. "Don't ignore alarm symptoms": Difficulty swallowing, weight loss, or blood in vomit/stool need urgent medical attention.
4. "Lifestyle changes help": Stopping smoking, reducing alcohol, and managing stress can improve symptoms.

---

14. Quality Markers & Audit Standards

---

15. Historical Context & Interesting Facts

Discovery of Helicobacter pylori (1982)

• Barry Marshall and Robin Warren isolated H. pylori from gastric biopsies and proposed it caused gastritis and peptic ulcers.
• 1984: Marshall drank a Petri dish of H. pylori to prove causation. He developed acute gastritis, biopsied his own stomach, and demonstrated the bacteria.
• Paradigm shift: Peptic ulcer disease transformed from a chronic surgical condition to a curable infectious disease.
• 2005: Nobel Prize in Physiology or Medicine awarded to Marshall and Warren. [6]

The PPI Revolution (1989)

• Omeprazole (first PPI) launched in 1989. Revolutionized acid suppression therapy.
• Before PPIs, H2 receptor antagonists (ranitidine) were standard; PPIs provided superior acid control.
• PPIs became the most prescribed drug class globally by the 2000s.

Rome Criteria Evolution

• Rome I (1989) → Rome IV (2016): Progressive refinement of functional GI disorder definitions.
• Rome IV (2016): Introduced EPS/PDS subtypes for functional dyspepsia, recognizing heterogeneous pathophysiology. [8]

---

16. Functional Dyspepsia: Biopsychosocial Model

Functional dyspepsia is increasingly understood as a disorder of brain-gut interaction, not purely psychological or purely gastric. [13]

Key Components:

1. Biological: Visceral hypersensitivity, impaired accommodation, delayed emptying, duodenal eosinophilia.
2. Psychological: Anxiety, depression, catastrophizing, somatization.
3. Social: Stress, early life trauma, cultural factors.

Management should address all three domains:

• Biological: PPIs, prokinetics, TCAs.
• Psychological: CBT, mindfulness, hypnotherapy.
• Social: Stress reduction, patient education, reassurance.

---

17. References

1. Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol. 2017;112(7):988-1013. PMID: 28631728

2. Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut. 2015;64(7):1049-1057. PMID: 25147201

3. Talley NJ, Ford AC. Functional Dyspepsia. N Engl J Med. 2015;373(19):1853-1863. PMID: 26535514

4. Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology. 2006;131(2):390-401. PMID: 16890592

5. National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. NICE Clinical Guideline CG184. 2014 (updated 2019). nice.org.uk/guidance/cg184

6. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374(9699):1449-1461. PMID: 19683340

7. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724-1762. PMID: 35944925

8. Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380-1392. PMID: 27147122

9. Enck P, Azpiroz F, Boeckxstaens G, et al. Functional dyspepsia. Nat Rev Dis Primers. 2017;3:17081. PMID: 29154369

10. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. NICE Guideline NG12. 2015 (updated 2021). nice.org.uk/guidance/ng12

11. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-239. PMID: 28071659

12. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection -- a critical review. Aliment Pharmacol Ther. 2004;20(10):1001-1017. PMID: 15569102

13. Van Oudenhove L, Vandenberghe J, Geeraerts B, et al. Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation? Gut. 2008;57(12):1666-1673. PMID: 18625692

14. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008;135(1):41-60. PMID: 18549814

15. Banks M, Graham D, Jansen M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68(9):1545-1575. PMID: 31278206

16. Aro P, Talley NJ, Johansson SE, Agréus L, Ronkainen J. Anxiety is linked to new-onset dyspepsia in the Swedish population: a 10-year follow-up study. Gastroenterology. 2015;148(5):928-937. PMID: 25644097

17. Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl. 1999;231:3-8. PMID: 10565617

18. Ford AC, Forman D, Bailey AG, et al. Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol. 2007;102(5):957-965. PMID: 17313494

19. Zagari RM, Law GR, Fuccio L, et al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. Gastroenterology. 2010;138(4):1302-1311. PMID: 20074574

20. Endoh K, Leung FW. Effects of smoking and nicotine on the gastric mucosa: a review of clinical and experimental evidence. Gastroenterology. 1994;107(3):864-878. PMID: 8076773

21. Tack J, Demedts I, Dehondt G, et al. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology. 2002;122(7):1738-1747. PMID: 12055579

22. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;115(6):1346-1352. PMID: 9834261

23. Talley NJ, Locke GR 3rd, Lam C, et al. Functional dyspepsia in patients with diabetes mellitus: frequency and impact on quality of life. Am J Gastroenterol. 2001;96(9):2661-2665. PMID: 11569692

24. Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63(2):262-271. PMID: 23474420

25. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;(2):CD002096. PMID: 16625554

26. Fransen GA, Janssen MJ, Muris JW, Laheij RJ, Jansen JB. Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy. Aliment Pharmacol Ther. 2004;20(10):1045-1052. PMID: 15569106

27. Puli SR, Reddy JB, Bechtold ML, et al. Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review. Ann Surg Oncol. 2009;16(5):1255-1265. PMID: 19219507

28. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter. 2004;9(4):347-368. PMID: 15270750

29. Mégraud F, Lehours P. Helicobacter pylori Detection and Antimicrobial Susceptibility Testing. Clin Microbiol Rev. 2007;20(2):280-322. PMID: 17428887

30. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354(22):2340-2348. PMID: 16738270

31. Duncanson KR, Talley NJ, Walker MM, Burrows TL. Food and functional dyspepsia: a systematic review. J Hum Nutr Diet. 2018;31(3):390-407. PMID: 29266438

32. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;(12):CD008337. PMID: 24338763

33. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870-878. PMID: 26848182

34. Pinto-Sanchez MI, Yuan Y, Hassan A, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;11(11):CD011194. PMID: 29165787

35. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017;152(4):706-715. PMID: 28257716

36. Hsu YC, Liou JM, Yang TH, et al. Prokinetic agents for dyspepsia in patients with diabetes mellitus: systematic review and meta-analysis. BMJ Open. 2014;4(11):e006251. PMID: 25421341

37. Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821-828. PMID: 22157503

38. Ford AC, Luthra P, Tack J, Boeckxstaens GE, Moayyedi P, Talley NJ. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut. 2017;66(3):411-420. PMID: 26657899

39. Tack J, Ly HG, Carbone F, et al. Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss. Clin Gastroenterol Hepatol. 2016;14(3):385-392. PMID: 26538208

40. Soo S, Moayyedi P, Deeks J, Delaney B, Lewis M, Forman D. Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2005;(2):CD002301. PMID: 15846633

41. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173-179. PMID: 20638563

42. Barkun AN, Almadi M, Kuipers EJ, et al. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. Ann Intern Med. 2019;171(11):805-822. PMID: 31634917

43. Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion. 2011;84(2):102-113. PMID: 21494041

44. Talley NJ, Weaver AL, Zinsmeister AR. Smoking, alcohol, and nonsteroidal anti-inflammatory drugs in outpatients with functional dyspepsia and among dyspepsia subgroups. Am J Gastroenterol. 1994;89(4):524-528. PMID: 8147352

45. Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136(6):1863-1873. doi:10.1053/j.gastro.2009.01.073 PMID: 19457415

46. Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15(3):306-316. doi:10.1016/j.chom.2014.02.008 PMID: 24629337

47. Robinson K, Kenefeck R, Pidgeon EL, et al. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut. 2008;57(10):1375-1385. doi:10.1136/gut.2007.137539 PMID: 18467372

48. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev. 2008;88(4):1547-1565. doi:10.1152/physrev.00004.2008 PMID: 18923189

49. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology. 2004;127(4):1239-1255. doi:10.1053/j.gastro.2004.05.030 PMID: 15481001

50. Quartero AO, de Wit NJ, Lodders AC, Numans ME, Smout AJ, Hoes AW. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci. 1998;43(9):2028-2033. doi:10.1023/a:1018855125396 PMID: 9753268

51. Mertz H, Fullerton S, Naliboff B, Mayer EA. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut. 1998;42(6):814-822. doi:10.1136/gut.42.6.814 PMID: 9691920

52. Wauters L, Talley NJ, Walker MM, Tack J, Vanuytsel T. Novel concepts in the pathophysiology and treatment of functional dyspepsia. Gut. 2020;69(3):591-600. doi:10.1136/gutjnl-2019-318536 PMID: 31563878

53. Van Oudenhove L, Vandenberghe J, Dupont P, et al. Regional brain activity in functional dyspepsia: a H(2)(15)O-PET study on the role of gastric sensitivity and abuse history. Gastroenterology. 2010;139(1):36-47. doi:10.1053/j.gastro.2010.04.015 PMID: 20406640

54. Zhong L, Shanahan ER, Raj A, Koloski NA, Fletcher L, Morrison M, et al. Dyspepsia and the microbiome: time to focus on the small intestine. Gut. 2017;66(6):1168-1169. doi:10.1136/gutjnl-2016-312574 PMID: 27489241

55. Kuo B, McCallum RW, Koch KL, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008;27(2):186-196. doi:10.1111/j.1365-2036.2007.03564.x PMID: 17973643

56. Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67(7):1351-1362. doi:10.1136/gutjnl-2017-314722 PMID: 29437910

57. Boyce M, Thomsen L, Clelland C, Venkova K. Metoclopramide and domperidone: pharmacology and clinical use in gastroenterology. Gastroenterol Clin North Am. 2021;50(3):489-507. doi:10.1016/j.gtc.2021.03.003 PMID: 34304771

58. Tack J, Janssen P, Masaoka T, Farré R, Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol. 2012;10(11):1239-1245. doi:10.1016/j.cgh.2012.06.036 PMID: 22813445

59. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377(9769):905-913. doi:10.1016/S0140-6736(11)60020-2 PMID: 21345487

60. Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: current status and future concepts. World J Gastroenterol. 2014;20(18):5283-5293. doi:10.3748/wjg.v20.i18.5283 PMID: 24833858

61. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12(4):275-278. doi:10.1111/j.1523-5378.2007.00518.x PMID: 17669098

62. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20(3):153-167. doi:10.2133/dmpk.20.153 PMID: 15988117

63. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359(9300):14-22. doi:10.1016/S0140-6736(02)07273-2 PMID: 11809181

64. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002;359(9300):9-13. doi:10.1016/S0140-6736(02)07272-0 PMID: 11809180

65. Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731-1738. doi:10.1136/gut.2005.080754 PMID: 16687434

66. Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019-1026. doi:10.1136/gutjnl-2019-319954 PMID: 31619466

67. Suzuki H, Matsuzaki J, Fukushima Y, et al. Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia--a multicenter, double-blind, randomized, placebo-controlled study. Neurogastroenterol Motil. 2014;26(7):950-961. doi:10.1111/nmo.12348 PMID: 24766295

68. Melzer J, Rösch W, Reichling J, Brignoli R, Saller R. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther. 2004;20(11-12):1279-1287. doi:10.1111/j.1365-2036.2004.02275.x PMID: 15606389

69. Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology. 2003;125(2):421-428. doi:10.1016/s0016-5085(03)00878-3 PMID: 12891544

70. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method". Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(7):405-414. doi:10.2183/pjab.87.405 PMID: 21785258

71. Liao Z, Hou X, Lin-Hu EQ, et al. Accuracy of magnetically controlled capsule endoscopy, compared with conventional gastroscopy, in detection of gastric diseases. Clin Gastroenterol Hepatol. 2016;14(9):1266-1273. doi:10.1016/j.cgh.2016.05.013 PMID: 27211503

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Always consult current local guidelines and seek senior advice for individual patient management. If you have persistent dyspepsia or alarm symptoms, please consult a healthcare professional urgently.